Table 2.
Therapies associated with potential late effects on recently conducted clinical trials in children and adolescents with ALL
IT indicates intrathecal; HD-methotrexate, high-dose methotrexate; SCT, stem cell transplantation; CR, complete remission; SR, standard risk; IR, intermediate risk; HR, high risk; NHR, non-high risk; VHR, very high risk; and LR, low risk.
*Dose: 1–5 g/m2.
†All patients received 5–10 doses of escalating dose IV methotrexate (100–350 mg/m2).
